LRIG1 and neoplasm: To analyse the effect of Lrig1 loss on the tumour-initiating capacity of GSCs we employed two approaches: first, ex vivo GSC transplantation of Lrig1 WT or Lrig1 KO GSCs into organotypic slice cultures (Marques-Torrejon et al., 2018) (Figure 3A); and second, in vivo transplantation into immunocompromised (NSG) mice.